Effects of chloroquine pretreatment on antidonor alloantibody production5-150
| Untreated Cell . | Pretreated Cell . | Chloroquine Concentration . | N . | Transfusion Week . | ||
|---|---|---|---|---|---|---|
| Pre . | 2 . | 4 . | ||||
| APC/platelets5-151 | — | 0 | 33 | 05-152 | 45 — | 70 — |
| APC | Platelets | 0.1 mM | 14 | 0 | 55 (n/s)5-153 | 85 (n/s) |
| Platelets | APC | 0.1 mM | 8 | 0 | 100 (P < .01) | 100 (P < .1) |
| Untreated Cell . | Pretreated Cell . | Chloroquine Concentration . | N . | Transfusion Week . | ||
|---|---|---|---|---|---|---|
| Pre . | 2 . | 4 . | ||||
| APC/platelets5-151 | — | 0 | 33 | 05-152 | 45 — | 70 — |
| APC | Platelets | 0.1 mM | 14 | 0 | 55 (n/s)5-153 | 85 (n/s) |
| Platelets | APC | 0.1 mM | 8 | 0 | 100 (P < .01) | 100 (P < .1) |
APC or donor platelets were pretreated with chloroquine and then used in the APC pulsing assay, washed twice and 106 APC were transfused weekly.
Data for the untreated APC/platelet cultures (n = 33) are included from Table 2 for statistical comparison.
Data are expressed as the percentage of recipients with detectable antidonor antibody by flow cytometry (rounded to nearest 5%).
The χ2 test of independent proportions was used to compare the agent-treated pulsed APC groups against the nontreated pulsed APC group. (n/s indicates not significant).